MAY 12, 2020 8:43 PM PDT

Novel Drug Approved for Non-Small Cell Lung Cancer

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung cancer (NSCLC). The therapeutic called ‘Tabrecta™ (capmatinib, formerly INC280)’ is an oral MET inhibitor for patients with a METex14 mutation in their tumors.

Learn more about non-small cell lung cancer (NSCLC):

 

 

“Non-small cell lung cancer is a complex disease, with many different possible mutations that may encourage the cancer’s growth,” said Juergen Wolf, MD, from the Center for Integrated Oncology, University Hospital Cologne and lead investigator of the GEOMETRY study. “MET exon 14 skipping is a known oncogenic driver. With today’s decision by the FDA, we can now test for and treat this challenging form of lung cancer with targeted therapy, offering new hope for patients with NSCLC harboring this type of mutation.”

The approval of Trabecta is based on findings from the pivotal GEOMETRY mono-1 Phase II clinical trial. The most common side-effects noted were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

“Today, and especially during these difficult times, we are incredibly proud that Tabrecta is the first treatment approved by the FDA specifically to treat patients diagnosed with this aggressive NSCLC associated with METex14,” said Susanne Schaffert, PhD, President, Novartis Oncology. “In our quest to reimagine medicine, we have worked tirelessly over the past decades to advance the understanding and treatment of NSCLC, striving to make a difference in patients’ lives, one mutation at a time. We thank all the physicians, patients and families involved in the Tabrecta clinical trials, and we remain committed to advancing innovative solutions for the patients we work to serve.”

Source: Novartis

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 31, 2020
Drug Discovery & Development
Researchers Reverse Advanced Alzheimer's in Mice
JUL 31, 2020
Researchers Reverse Advanced Alzheimer's in Mice
Researchers from Macquarie University have found a way to reverse the effects of memory loss in mice with advanced demen ...
AUG 11, 2020
Drug Discovery & Development
FDA Approves New Opioid for Short-Term Use
AUG 11, 2020
FDA Approves New Opioid for Short-Term Use
The US Food and Drug Administration has announced the approval of Olinvyk (oliceridine), a new opioid that can help mana ...
AUG 12, 2020
Drug Discovery & Development
Fast Tracking Drug Therapies
AUG 12, 2020
Fast Tracking Drug Therapies
Fast-tracking drugs in a safe and effective way can eventually save the lives of many from life-threatening diseases. Ne ...
AUG 11, 2020
Drug Discovery & Development
Engineering Drug-Producing Bacteria
AUG 11, 2020
Engineering Drug-Producing Bacteria
Researchers at Rice University worked to program a bacterium, Escherichia coli, to produce a synthetic "noncanonica ...
AUG 24, 2020
Drug Discovery & Development
New Drug Reduces Swelling in Asthma and COPD
AUG 24, 2020
New Drug Reduces Swelling in Asthma and COPD
Researchers from the University of Glasgow, Scotland, and the University of Technology Sydney in Australia have identifi ...
SEP 20, 2020
Cell & Molecular Biology
Revealing the Structure of Hallucinogens Bound to Their Receptor
SEP 20, 2020
Revealing the Structure of Hallucinogens Bound to Their Receptor
Recent studies have demonstrated that hallucinogenic drugs like LSD, psilocybin, and mescaline have therapeutic potentia ...
Loading Comments...